Hologic INC 10-Q quarterly reports

Hologic reports mixed first-quarter financial results with a slight revenue increase, a dip in net income, and a significant pending acquisition by Blackstone and TPG.

Hologic, Inc. reported a slight increase in quarterly net income to $194.9 million, but a substantial decline in nine-month net income to $378.5 million, primarily driven by $220.9 million in intangible asset impairment charges related to recent acquisitions.

Hologic reports a net loss for Q2 2025 due to significant intangible asset impairment charges, despite completing the acquisition of Gynesonics and experiencing revenue growth in certain segments.

Hologic's first quarter fiscal 2025 reveals a mixed performance, with diagnostics growth offsetting declines in breast health and skeletal health revenues.

Hologic's Q3 results show a mixed performance with revenue growth in some segments offset by declines in others, alongside strategic restructuring and asset sales.

Hologic's second quarter results show a decrease in revenue compared to the prior year, primarily due to declining COVID-19 assay sales, alongside strategic restructuring and asset sales.

Hologic's first quarter results show a decrease in revenue due to reduced COVID-19 testing demand, alongside strategic restructuring and asset sales.